OncoGenex/Teva Alter Late-Stage Custirsen Program
This article was originally published in The Pink Sheet Daily
Teva and OncoGenex announced changes to the Phase III program of their prostate cancer drug custirsen on the heels of positive data from a competitor.
You may also be interested in...
Vitae and partner Boehringer Ingelheim to start over in Alzheimer’s with new compound, shelving lead drug due to skin reactions. OncoGenex sees subgroup data providing a potential niche indication for custirsen, while Cara is ready to begin Phase III with its intravenous candidate for post-surgical acute pain.
Plus news on recent financing activity by Aastrom Biosciences, Tarsa Therapeutics, OncoGenex and Medivation.
OncoGenex raises $50 million in cash to support the development of its earlier stage oncology assets.